Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12,057 GBX | +0.58% | +7.38% | +13.96% |
04:27pm | AstraZeneca Says Enhertu Phase 3 Trial Shows 'Statistically Significant' Progression-Free Breast Cancer Survival Improvement | MT |
02:55pm | ASTRAZENECA : JP Morgan maintains a Buy rating | ZD |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.96% | 231B | |
+26.95% | 661B | |
+27.32% | 566B | |
-6.41% | 352B | |
+20.39% | 332B | |
+2.78% | 283B | |
+5.16% | 200B | |
-9.12% | 195B | |
-5.00% | 145B | |
-10.46% | 144B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- AstraZeneca's Rare Inflammatory Disease Wins EU Health Agency's Positive Recommendation